Document ID: chunk:federal_register_of_legislation:F2023L01747:schedule:1:p5
Version: federal_register_of_legislation:F2023L01747
Segment Type: schedule
Provision Reference: sch 1 (pt 5/31)
Character Range: 14275–17331

C11631 C11635 C11704 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11759 C11761 C11767 C11852 C11853 C11854 C11855 C11861 C11865 C11867 C11903 C11906 C11966 C12098 C12101 C12122 C12123 C12147 C12148 C12155 C12156 C12157 C12158 C12174 C12189 C12190 C12194 C12212 C12214 C12228 C12240 C13556 C13599 C13602 C13609 C13612 C13650 C13681 C13694 C14377 C14378 C14483 C14486 C14488 C14493 C14496 C14498 C14499 C14507 C14567 C14568 C14590 C14655 C14656 C14662 C14670 C14672 C14673 C14683 C14701 C14713 C14730  P9715 P11709 P11715 P11716 P11759 P11761 P11852 P11854 P11855 P12098 P12101 P12147 P13602 P13609  2  2  2

     [16]               Schedule 1, Part 1, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe [Maximum Quantity: 2; Number of Repeats: 3]
     insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":
            Adalicip  LR  MP  C9064 C9386 C9715 C11107 C11523 C11524 C11579 C11604 C11606 C11631 C11635 C11704 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11759 C11761 C11767 C11852 C11853 C11854 C11855 C11861 C11865 C11867 C11903 C11906 C11966 C12098 C12101 C12122 C12123 C12147 C12148 C12155 C12156 C12157 C12158 C12174 C12189 C12190 C12194 C12212 C12214 C12228 C12240 C13556 C13599 C13602 C13609 C13612 C13650 C13681 C13694 C14377 C14378 C14483 C14486 C14488 C14493 C14496 C14498 C14499 C14507 C14567 C14568 C14590 C14655 C14656 C14662 C14670 C14672 C14673 C14683 C14701 C14713 C14730  P9064 P9386 P11861 P12174 P12194 P13599 P13650 P13681 P13694 P14483 P14486 P14488 P14496 P14498 P14568 P14590 P14655 P14662 P14670 P14672 P14673  2  3  2

     [17]               Schedule 1, Part 1, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe [Maximum Quantity: 2; Number of Repeats: 4]
     insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":
            Adalicip  LR  MP  C9064 C9386 C9715 C11107 C11523 C11524 C11579 C11604 C11606 C11631 C11635 C11704 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11759 C11761 C11767 C11852 C11853 C11854 C11855 C11861 C11865 C11867 C11903 C11906 C11966 C12098 C12101 C12122 C12123 C12147 C12148 C12155 C12156 C12157 C12158 C12174 C12189 C12190 C12194 C12212 C12214 C12228 C12240 C13556 C13599 C13602 C13609 C13612 C13650 C13681 C13694 C14377 C14378 C14483 C14486 C14488 C14493 C14496 C14498 C14499 C14507 C14567 C14568 C14590 C14655 C14656 C14662 C14670 C14672 C14673 C14683 C14701 C14713 C14730  P11107 P12155 P12212 P13556 P13612 P14377 P14378  2  4  2

     [18]               Schedule 1, Part 1, entry for Adalimumab in the form Injection 40 mg in 0.4 mL pre-filled syringe [Maximum Quantity: 2; Number of Repeats: 5]
     insert in the columns in the order indicated, and in alphabetical order for the column headed "Brand":
            Adalicip  LR  MP  C9064 C9386 C9715 C11107 C11523 C11524 C11579 C11604 C11606 C11631 C11635 C11704 C11709 C11711 C11713 C11715 C11716 C11717 C11718 C11759 C11761 C11767 C11852 C11853 C11854 C11855 C11861